Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Ticker
$BIIB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
7,605
ISIN
US09062X1037
Website
Biogen Metrics
BasicAdvanced
$19B
13.15
$10.12
0.15
-
Price and volume
Market cap
$19B
Beta
0.15
52-week high
$238.00
52-week low
$110.04
Average daily volume
1.4M
Financial strength
Current ratio
1.44
Quick ratio
0.867
Long term debt to equity
28.695
Total debt to equity
38.997
Interest coverage (TTM)
9.84%
Profitability
EBITDA (TTM)
3,080.9
Gross margin (TTM)
75.67%
Net profit margin (TTM)
15.07%
Operating margin (TTM)
24.16%
Effective tax rate (TTM)
15.58%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
5.43%
Return on equity (TTM)
9.19%
Valuation
Price to earnings (TTM)
13.15
Price to revenue (TTM)
1.976
Price to book
1.15
Price to tangible book (TTM)
21.25
Price to free cash flow (TTM)
8.136
Free cash flow yield (TTM)
12.29%
Free cash flow per share (TTM)
1,634.97%
Growth
Revenue change (TTM)
1.59%
Earnings per share change (TTM)
26.39%
3-year revenue growth (CAGR)
-3.19%
10-year revenue growth (CAGR)
-0.31%
3-year earnings per share growth (CAGR)
1.16%
10-year earnings per share growth (CAGR)
-3.09%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Bulls say / Bears say
Biogen's Alzheimer's drug, Leqembi, generated $40 million in sales in Q2 2024, surpassing Wall Street expectations and indicating strong market potential. (reuters.com)
The acquisition of Reata Pharmaceuticals added Skyclarys to Biogen's portfolio, which generated $78 million in Q1 2025, exceeding forecasts and enhancing the company's rare disease pipeline. (nasdaq.com)
Biogen's cost-cutting initiatives, including a $1 billion restructuring program, are expected to generate significant savings, allowing reinvestment into new products and R&D. (nasdaq.com)
Biogen anticipates a mid-single-digit percentage revenue decline in 2025, excluding currency impacts, due to strong competition for its multiple sclerosis drugs. (reuters.com)
The launch of Leqembi has been slow in the U.S. due to complex requirements, including diagnostic tests and regular brain scans, potentially hindering its market adoption. (reuters.com)
Biogen's multiple sclerosis drug sales, including Tecfidera, fell by 4.9% to $1.15 billion in Q2 2024, reflecting ongoing challenges in its core business. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
GlobeNewsWire·16 hours ago
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewsWire·2 weeks ago
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $19B as of July 11, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 13.15 as of July 11, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.